Pharmaceutical Biology · 2023 · 12 citations · 22 references
MedicineNephrologyPharmacologyMolecular PharmacologyRenal PathophysiologySystems PharmacologyDiabetic Kidney DiseaseDiabetic NephropathyRenal DiseaseRenal PharmacologyAdvanced Glycation End ProductsDiabetic Kidney Disease ProgressionHerbal Compound Network AnalysisPharmacological Network AnalysisPharmacological ProfilingProximal Tubular DysfunctionRenoprotective Therapies
Context Diabetic nephropathy (DN) is the main cause of end-stage renal disease. Modified Shen-Yan-Fang-Shuai formula (M-SYFSF) has excellent clinical efficacy in treating diabetic kidney disease. However, the potential mechanism of M-SYFSF remains unknown.Objective To investigate the mechanism of M-SYFSF against DN by network pharmacological analysis and biological experiments.Materials and methods Utilizing a web-based pharmacology database, the potential mechanisms of M-SYFSF against DN were identified. In vivo experiments, male SD rats were injected with streptozotocin (50 mg/kg) and got uninephrectomy to construct a model of DN. M-SYFSF (11.34 g/kg/d) was gavaged once per day for 12 weeks after model establishment. In vitro experiments, human proximal tubular cells (HK-2) were performed with advanced glycation end-products (AGEs) (100 μg/mL), then intervened with M-SYFSF freeze-dried powder. Pathological staining, WB, IHC, ELISA were conducted to explore the mechanism of M-SYFSF against DN.Results Network pharmacological analysis showed that MAPK pathway was the potential pathway. Results showed that compared with the Model group, M-SYFSF significantly reduced 24h urine albumin, UACR, and serum creatinine levels (54.90 ± 26.67 vs. 111.78 ± 4.28, 8.87 ± 1.69 vs. 53.94 ± 16.01, 11.56 ± 1.70 vs. 118.70 ± 49.57, respectively), and improved renal pathological changes. Furthermore, the intervention of M-SYFSF reduced the expression of pro-inflammatory cytokines and inhibited the activation of MAPK pathway in AGEs-treated HK-2 cells.Discussion and conclusion M-SYFSF is likely to reduce inflammation in DN by inhibiting the MAPK pathway. It provides a theoretical basis for the clinical application of M-SYFSF in the treatment of DN.
22
International Diabetes Federation 2017
Ann M. Carracher, Payal H. Marathe, Kelly L. Close · Journal of Diabetes · 2018 · 13.6K citations · Full text
Medicine, Endocrinology, Diabetology +11
TCMSP: a database of systems pharmacology for drug discovery from herbal medicines
Jinlong Ru, Peng Li, Jinan Wang et al. · Journal of Cheminformatics · 2014 · 5K citations · Full text
Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000–2015
Hui‐Teng Cheng, Xiaoqi Xu, Paik‐Seong Lim et al. · Diabetes Care · 2020 · 318 citations · Full text
Jean‐Philippe Gratton, Manuel Morales‐Ruiz, Yasuko Kureishi et al. · Journal of Biological Chemistry · 2001 · 282 citations · Full text